DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/72gslm/the_2016_tb) has announced the addition of the "The 2016 TB Summit (London, UK - 21st-23rd June 2016)" conference to their offering.
This annual three day event will explore new research into TB detection, treatment and vaccination as well as new development in controlling and preventing Mycobacterium tuberculosis Infection.
With an informal academic atmosphere and international speakers, it is the perfect environment for debate and discussion.
Who Should Attend?
This event welcomes those working within tuberculosis research and treatment, drug discovery, global health, physicians and those working on novel technologies related to TB detection and control.
- Integrated interdisciplinary approaches to tackle extensively drug resistance in TB
- Host defence mechanisms during early stages of tuberculosis in zebrafish
- TB in healthcare workers
- Intracellular growth of Mycobacterium tuberculosis; linking microbial physiology to drug development.
- TB persisters - resistance is futile, time to end them all
- Coughing and the transmission of tuberculosis
- A vaccine pipeline - phage display for biomarker identification and generation of human antibodies for diagnostics and therapy
- The biosynthesis of Mtb polymethylated polysaccharides, potential new targets for drug discovery
- Understanding and intervening in HIV-tuberculosis
- Extensive Drug Resistant Tuberculosis plus Linezolid Resistance: Linezolid resistance development in Lisbon, Portugal
- Development of Dinitrobenzyl Oxadiazoles and Thiadiazoles as Selective Antitubercular Agents
- Rapid differentiation of Mycobacteria
- Design and synthesis of antitubercular small molecules targeting drug-resistant mycobacteria
- A clinical TB trial in Ethiopia
- The Mtb Divisome: Initial Structural Efforts on Drug Targets
- TaqMan Array Card for genotypic drug resistance testing
- Plant natural products for TB treatment and prophylaxis
- The role of human gamma/delta T cells in the immunity against the infection of Mycobacterium tuberculosis.
- Communicating risks and benefits of preventive tuberculosis treatment for shared decision making
- Metabolomics, for application to new TB biomarker discovery for better characterising and diagnosing TB
- Measuring mutations causing drug resistance and antibiotic susceptibility by point of care devices
For more information visit http://www.researchandmarkets.com/research/72gslm/the_2016_tb